Skip to main content
Fig. 2 | Infectious Diseases of Poverty

Fig. 2

From: Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials

Fig. 2

Incidence of adverse events following immunization for different vaccine modalities. BBBIBP-CorV designed by the Beijing Institute of Biological Products; WCoronaVac designed by the Wuhan Institute of Biological Products; COVID-19 vaccines in the Phase I Trial; COVID-19 vaccines in the Phase II Trial; *COVID-19 vaccines on first vaccination; **COVID-19 vaccines on second vaccination; b1BNT162b1 in the Phase I Trial; b2BNT162b2 in the Phase I Trial. RR risk ratio, CI confidence interval, mRNA messenger ribonucleic acid

Back to article page